Evidence map›Paper›PMID 30317413›Full record

ArticleJournal of thrombosis and thrombolysis2019

Ruling out deep vein thrombosis in patients with superficial vein thrombosis: external validation of the ICARO score.

Paul Frappé, Quentin Brosse, Benjamin Seffert, Hervé Décousus, Laurent Bertoletti, STEPH Study Group

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Superficial Venous Thrombosis: A Comprehensive Review.Healthcare (Basel, Switzerland) · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Paul FrappéDepartment of General Practice, University of Saint-Etienne, Saint-Etienne, France. paul.frappe@univ-st-etienne.fr.ORCID http://orcid.org/0000-0002-7350-2824
Quentin BrosseDepartment of General Practice, University of Saint-Etienne, Saint-Etienne, France.
Benjamin SeffertDepartment of Vascular Medicine and Therapeutics, CHU de Saint-Etienne, Saint-Etienne, France.
Hervé DécoususSainbiose DVH, Inserm U 1059, University of Saint-Etienne, Saint-Etienne, France.
Laurent BertolettiSainbiose DVH, Inserm U 1059, University of Saint-Etienne, Saint-Etienne, France.
STEPH Study Group
Inserm · FRCentre Hospitalier Universitaire de Saint-Étienne · FRUniversity of Geneva · CH

Funding

French Ministry of Health and Sports Programme Hospitalier de Recherche Clinique 2011
6 · The paper itself

Abstract

A clinical score was recently proposed to rule out concomitant DVT in patients with a clinical suspicion of SVT. This study aimed to assess the external validity of this score in patients from the STEPH study. We performed a post-hoc analysis of data from the STEPH study. The STEPH study was a prospective multicenter community-based study conducted during a 1-year period in the resident adult population of the Greater Saint-Etienne urban area (France). Every patient with a clinical suspicion of SVT underwent a venous compression ultrasonography, to confirm SVT and to assess the presence of a concomitant DVT or not. Odds ratios for concomitant DVT were calculated for each item of the ICARO score. We then computed the score for each patient, and performed a receiver operating characteristic (ROC) curve analysis. In univariate analysis, none of the ICARO items were significantly different given the presence of a concomitant DVT. Given computed scores, 55 patients (45.1%) had a low risk, 17 (13.9%) had an intermediate risk and 50 (41.0%) had a high risk of a concomitant DVT. The area under the ROC curve was 0.386 [95% CI, 0.268-0.504]. When risk levels were dichotomized as low vs intermediate-high risk, the ICARO score had a sensitivity of 36.0%, a specificity of 40.2%, a positive predictive value of 13.4% and a negative predictive value of 70.9%. Our study does not confirm the utility of the ICARO clinical score to rule out concomitant DVT in case of SVT.

Indexed as

Severity of Illness IndexAgedFemaleFranceHumansMaleMiddle AgedRisk AssessmentRisk FactorsROC CurveUltrasonographyVenous ThrombosisPulmonary embolismRisk factorsSaphenous veinUltrasonographyVenous thrombosis

Identifiers

PMID30317413
OpenAlexW2896851268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.